ArticlemedRxiv : the preprint server for health sciences2026
Rethinking anomia across the frontotemporal dementia spectrum: marker of language dysfunction or global cognitive decline?
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Anomia is common in frontotemporal dementia (FTD), although its clinical prominence varies by subtype, with the most marked impairment typically observed in primary progressive aphasia (PPA). It remains unclear whether naming impairment reflects language-specific impairment or broader cognitive severity, and how it relates to other cognitive domains across FTD syndromes. Methods: Fifteen healthy controls and twenty-two individuals across the FTD spectrum, including variant-specified and unclassifiable (NOS) presentations, completed two confrontation naming tasks (Boston Naming Test and Multilingual Naming Test) and a global cognitive screening measure (Montreal Cognitive Assessment, MoCA). Patient participants additionally completed a standardized language battery (Western Aphasia Battery - Revised) and a comprehensive neuropsychological assessment (Uniform Data Set). Naming performance was compared between groups and associations with language severity, global cognition, and domain-specific cognitive functions were examined using regression analyses. Results: Naming was impaired in patients relative to healthy controls but did not differ between patient groups. Naming was strongly associated with language severity, but not global cognition. A significant group-by-MoCA interaction indicated that MoCA was positively associated with naming only in the unclassifiable group. In addition, naming was associated with episodic memory across both verbal and non-verbal domains. Conclusions: Naming in FTD primarily reflects language severity rather than global cognitive impairment. A robust association between naming and episodic memory suggests potential contributions from semantic cognition, shared frontally mediated retrieval processes, or parallel cognitive decline. These findings support the use of naming as a marker of language dysfunction while highlighting its relevance to broader cognitive systems in FTD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.